SRI International

Executive Summary

SRI International is an independent nonprofit research institute headquartered in Menlo Park, California, with a legacy dating back to 1946. As a pioneer in Silicon Valley, SRI conducts multidisciplinary R&D for government agencies (e.g., DARPA, NIH) and commercial clients, focusing on artificial intelligence, digital health, and drug delivery. Its history includes inventing technologies such as the computer mouse, Siri, and numerous medical devices. SRI's business model relies on contract research, licensing, and spinouts, generating over $500 million in annual revenue. The institute employs ~2,500 researchers and holds a robust patent portfolio. By operating at the intersection of deep tech and societal needs, SRI consistently delivers transformative solutions in defense, healthcare, and sustainability. Recent initiatives emphasize AI-driven drug discovery and personalized medicine through its SRI Biosciences division. The institute has also expanded partnerships with the Department of Defense on autonomous systems. Given its stable government funding and proven innovation track record, SRI remains a key player in next-generation technology development. However, its nonprofit status means direct financial returns are less predictable than for venture-backed startups. Conviction is based on its enduring relevance in high-growth sectors and the potential for significant spinout value creation.

Upcoming Catalysts (preview)

• Q3 2026Major DARPA Contract Award for AI-Driven Autonomous Systems80% success
• Q2 2026Spinout of Digital Health Platform for Remote Patient Monitoring60% success
• Q1 2027Licensing Deal for Novel Drug Delivery Technology to Top Pharma50% success